Upcoming Events

No Current Upcoming Events

 


Search Site

 

 

Stock Price: TSX-V

Pacgen Biopharmaceuticals Corporation is a life science technology transfer company focused on the commercial development of novel therapeutic drug candidates up to Phase II, proof of concept efficacy in humans.

The Company identifies and sources innovative therapeutic drug candidates globally, and develops these drug candidates in accordance to the United States Food and Drug Administration regulatory standards to feed the product development pipelines of the pharmaceuticals industry.

The Company’s lead product, PAC-113, is an anti-fungal in a Phase II program for the treatment of oral Candidiasis. Pacgen recently reported positive efficacy results from its Phase IIb dose-ranging clinical trial of PAC-113. Pacgen also has an early stage research program. The most advanced candidate is a peptide therapeutic, PAC-G31P, which is being investigated in preclinical studies for its potential to treat inflammatory disease.

Latest News

July 30, 2010
Pacgen Reports Fiscal 2010 Financial Results

June 8, 2010
Pacgen Completes Share Consolidation

May 28, 2010
Pacgen Closes Private Placement Financing

April 19, 2010
Pacgen Announces Private Placement Financing and Financial Restructuring

> Archived News